BREAKING: Core CPI Inflation Unexpectedly DipsGSK (GSK) stock crumbled Friday after the Food and Drug Administration granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.The agency signed off on several combinations using Blenrep to treat multiple myeloma patients who've undergone at least three prior lines of therapy.GSK was gunning for a comeback with Blenrep. Blenrep won accelerated approval in 2020. But the drug failed its confirmatory study and GSK pulled it from the market in ...